Dark

INDP
Indaptus Therapeutics, Inc. Common Stock
stock NASDAQ

Market Open

Jul 7, 2025 12:23:38 PM EDT

11.36USD+2.435%(+0.27)75,022

0.00Bid 0.00Ask 0.00Spread

Pre-market

Jul 2, 2025 8:11:30 AM EDT

10.50USD-5.320%(-0.59)0

After-hours

Jul 3, 2025 4:33:30 PM EDT

10.11USD-9.164%(-1.02)0

OverviewHistoricalExchangesShortsNews

Jan 31, 2022

08:42AM EST HC Wainwright & Co. Assumes Indaptus Therapeutics at Buy, Announces Price Target of $15 Benzinga

Jan 5, 2022

07:00AM EST Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company), today announced that Jeffrey Meckler, Chief Executive Officer, will participate in a pre-recorded presentation at the H.C. Wainwright BioConnect 2022 Virtual Conference made available on Monday, January 10, 2022 at 7:00 a.m. ET. GlobeNewswire Inc

Jan 3, 2022

07:04AM EST Indaptus Therapeutics Appoints Boyan Litchev As Chief Medical Officer, Effective Jan 31 RTTNews

07:00AM EST Seasoned Drug Developer Brings More Than Twenty Years of Medical Leadership and Clinical Oncology Experience GlobeNewswire Inc

Dec 1, 2021

08:01AM EST Indaptus Therapeutics Appoints Mark Gilbert, M.D., to Board of GlobeNewswire Inc

Nov 15, 2021

10:57AM EST Indaptus Therapeutics Q3 EPS $(0.81) Up From $(0.95) YoY Benzinga

07:00AM EST Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company), today announces financial results for the third quarter ended September 30, 2021 and provides a corporate update. GlobeNewswire Inc

Oct 19, 2021

10:02AM EDT Benzinga's Top Ratings Upgrades, Downgrades For October 19, 2021 Benzinga

09:00AM EDT Maxim Group Upgrades Indaptus Therapeutics to Buy, Announces $16 Price Target Benzinga

Oct 7, 2021

08:24AM EDT The Daily Biotech Pulse: Moderna Invests In Africa, Amgen Announces Neuroscience R&D Collaboration, Decision Day For Chemocentryx, Biophytis To Restate Results Benzinga

Sep 24, 2021

03:25PM EDT Indaptus Therapeutics Filing Shows Registration For ~5.59M Share Common Stock Offering Benzinga

Sep 16, 2021

06:36AM EDT The following are some of the stocks making big moves in Thursday's pre-market trading (as of 6.20 A.M. EDT). RTTNews

Sep 15, 2021

02:42PM EDT Mid-Afternoon Market Update: Dow Jumps 250 Points; GreenSky Shares Spike Higher Benzinga

12:12PM EDT Mid-Day Market Update: Crude Oil Surges 3%; Kaival Brands Shares Plunge Benzinga

10:17AM EDT Mid-Morning Market Update: Markets Mixed; Industrial Production Rises 0.4% In August Benzinga

10:06AM EDT Shares of Indaptus Therapeutics, Inc. (INDP) more than doubled on Wednesday morning after the pre-clinical stage biotech company received notice of allowance from the U.S. Patent and Trademark Office for a strategic patent. RTTNews

07:38AM EDT The Daily Biotech Pulse: Lilly, Regeneron Ink COVID-19 Drug Deal With US, Regulatory Setback For Calliditas, Theravance To Cut 75% Jobs, 4 IPOs Benzinga

07:00AM EDT Indaptus Therapeutics, Inc. (Nasdaq: INDP) ("Indaptus" or the "Company), today announced that the United States Patent and Trademark Office has issued a notice of allowance for claims related to the Companys platform technology. GlobeNewswire Inc

Sep 14, 2021

07:50AM EDT The Daily Biotech Pulse: NRx Rises On COVID-19 Drug Collaboration, Amgen's Lung Cancer Drug Conditionally Approved In Canada, Coherus Data Readout Benzinga

Aug 18, 2021

07:38AM EDT The Daily Biotech Pulse: AzurRx Jumps On Data, Agios' Regulatory Application For Mitapivat Accepted For Priority Review, FDA Nod For GlaxoSmithKline Benzinga

Aug 17, 2021

08:28AM EDT The Daily Biotech Pulse: Lilly Reorganizes Business Units In Neuroscience Focus, Helius Medical Spikes On Breakthrough Designation, Ra Medical Sells Dermatology Business Benzinga

Aug 9, 2021

11:07AM EDT The Week Ahead In Biotech (Aug. 8-14): Jazz Pharma FDA Decision, Earnings Deluge and IPOs In The Spotlight Benzinga

Aug 6, 2021

07:42AM EDT The Daily Biotech Pulse: Dicerna Slips On Data, Novavax Tightlipped On US Vaccine Approval, Adagio IPO Benzinga

Aug 5, 2021

08:08AM EDT The Daily Biotech Pulse: Merck Reports Positive Keytruda Readout, Moderna Slips Despite Q2 Beat, Bayer To Buy Vividion For Up To $2B, GlycoMimetics Gets New CEO Benzinga

.dark-mode .zMJg17{ color: white; background-color: #333333; border: 2px solid white; }.light-mode .zMJg17{ color: #333333; background-color: white; border: 2px solid #333333; }INDPIndaptus Therapeutics, Inc. Common Stockstock NASDAQ

INDP
Indaptus Therapeutics, Inc. Common Stock
stock NASDAQ